论文部分内容阅读
目的:探讨口服蒿甲醚片(Artemether Tablet)对BALB/c小鼠CT-26结直肠癌的抑瘤作用。方法:BALB/c小鼠皮下接种CT-26结直肠癌细胞(2×106个/mL)48只,雌、雄各半;随机分为6组,每组8只,分别为Ⅰ组:蒿甲醚33.3mg/(kg.d)、Ⅱ组:蒿甲醚50mg/(kg.d)、Ⅲ组:蒿甲醚66.6mg/(kg.d)、Ⅳ组:蒿甲醚50mg/(kg.d)+硫酸亚铁1.5mg/(kg.d)组、Ⅴ组:阳性对照为卡培他滨片(83mg/kg.d)、Ⅵ组:空白对照组为等体积生理盐水;结果:口服蒿甲醚片33.3mg/(kg.d)、50mg/(kg.d)、66.6mg/(kg.d)以及蒿甲醚50mg/(kg.d)+硫酸亚铁1.5mg/(kg.d),对BALB/c小鼠CT-26结直肠癌的抑瘤率分别为:42.3%、51.4%、52.0%、53.5%,各实验组与生理盐水组比较,差异有显著性(分别P=0.024,P=0.006,P=0.007,P=0.004),各实验组间比较,差异无显著性(P>0.05)。各实验组与阳性对照组卡培他滨比较,除Ⅰ组:蒿甲醚33.3mg/(kg.d),差异有显著性(P<0.05)外,其余各组,统计差异无显著性(P>0.05)。结论:口服蒿甲醚片剂对小鼠CT-26结直肠癌有明显的抑制作用;蒿甲醚与硫酸亚铁合用能使抑瘤率增加。
Objective: To investigate the antitumor effect of artemether tablet on CT-26 colorectal cancer in BALB / c mice. Methods: BALB / c mice were inoculated subcutaneously with 48 CT-26 colorectal cancer cells (2 × 106 cells / mL), half female and half male. They were randomly divided into 6 groups (n = 8 each) (33.3mg / (kg.d)), Artemether 50mg / (kg.d), Artemether 66.6mg / (kg.d), Artemether 50mg / (kg .d) + ferrous sulfate 1.5mg / (kg.d) group, group V: capecitabine tablets (83mg / kg.d) positive control group Ⅵ: blank control group was equal volume of saline; Results: Oral artemether tablets 33.3mg / (kg.d), 50mg / (kg.d), 66.6mg / (kg.d) and artemether 50mg / (kg.d) + ferrous sulfate 1.5mg / (kg .d), the tumor inhibition rate of CT-26 colorectal cancer in BALB / c mice were 42.3%, 51.4%, 52.0% and 53.5%, respectively. There was significant difference between the experimental group and the saline group P = 0.024, P = 0.006, P = 0.007, P = 0.004). There was no significant difference between the experimental groups (P> 0.05). Each experimental group and the positive control group capecitabine, except for the group Ⅰ: artemether 33.3mg / (kg.d), the difference was significant (P <0.05), the remaining groups, the statistical difference was not significant P> 0.05). CONCLUSION: Oral artemether tablet can significantly inhibit the growth of murine CT-26 colorectal cancer. Combined use of artemether and ferrous sulphate can increase the tumor inhibition rate.